Literature DB >> 19266846

Minor salivary gland tumours in a Nigerian hospital: a retrospective review of 146 cases.

O M Gbotolorun1, G T Arotiba, O A Effiom, O G Omitola.   

Abstract

PURPOSE: This is a retrospective study of the location, diagnosis, sex and age distribution and treatment of minor salivary glands tumours of the upper aero digestive tract in Lagos, Nigeria.
MATERIAL AND METHODS: Case files and radiographs of patients treated over a 24-year period were reviewed.
RESULTS: These tumours constituted 40.4% of all salivary gland tumours in the series. The majority (62.3%) of these tumours was malignant, and the most common malignant tumour was mucoepidermoid carcinoma (19.2%). However, pleomorphic adenoma (34.2%) was the most common tumour overall. Both benign (67.2%) and malignant (23.9%) tumors were most frequently located in the palate. Both sexes were equally affected (Male-female ratio 1 to 1), but a higher proportion of benign tumours were found in the palate of females (75%) than their male counterparts (64%). Patients with adenoid cystic carcinoma were significantly older at presentation than those with pleomorphic adenoma and adenocarcinoma (P < 0.05).
CONCLUSION: These findings show that majority of these tumours were malignant (62.3%), though pleomorphic adenoma was the most common tumour. They also confirm the high predilection of pleomorphic adenoma (61.8%) for the palate of Black Africans.

Entities:  

Mesh:

Year:  2008        PMID: 19266846

Source DB:  PubMed          Journal:  Odontostomatol Trop        ISSN: 0251-172X


  2 in total

1.  Primary Epithelial Minor Salivary Gland Tumors in South Africa: A 20-Year Review.

Authors:  Yaseer Mahomed; Shabnum Meer
Journal:  Head Neck Pathol       Date:  2019-12-23

2.  Minor salivary gland mucoepidermoid carcinoma in children and adolescents: a case series and review of the literature.

Authors:  Priyanshi Ritwik; Kitrina G Cordell; Robert B Brannon
Journal:  J Med Case Rep       Date:  2012-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.